Loading...
Future FDA Approvals Will Expand Rare Disease Treatments
AnalystConsensusTarget's Fair Value
US$20.60
70.1% undervalued intrinsic discount04 Sep
US$6.16
1Y
-66.7%7D
-19.2%1Y
-66.7%7D
-19.2%You can edit this narrative until May 12 6:02 AM. Then, changes will post as Updates.